1 Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: lazarevicv@mail.nih.gov.
2 Primal Therapies, Inc., Menlo Park, CA 94025, USA.
3 Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
In this issue of Immunity, Iwata et al. (2017) report that the transcription factor T-bet acts as a selective repressor of the type I interferon (IFN) transcriptional program in response to IFN-γ signaling.